Loading...
The FDA recently approved a new progestin-only pill (POP; Slynd); each pack contains twenty-four 4-mg drospirenone tablets and four inert tablets. This dosage is higher than the 3 mg found in ethinyl estradiol/drospirenone oral contraceptive (OC) formulations (Yasmin, Yaz, and generics).
In efficacy trials that included 953 participants aged ≤35, the Pearl index (percentage of women conceiving during the first year of use) was 4.0, comparable to the failure rate observed in U.S. trials of estrogen-progestin pills and patches. Incidence of scheduled bleeding or spotting fell from 81% in Cycle 1 to 26% in Cycle 13, whereas unscheduled bleeding or spotting fell from 61% to 40%. These observations suggest that, while scheduled withdrawal bleedin…